Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EBITDA (2016 - 2023)

Historic EBITDA for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $53.8 million.

  • RedHill Biopharma's EBITDA rose 35898.73% to $53.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $56.6 million, marking a year-over-year increase of 43493.38%. This contributed to the annual value of -$14613.0 billion for FY2024, which is 10380772528.95% down from last year.
  • According to the latest figures from Q2 2023, RedHill Biopharma's EBITDA is $53.8 million, which was up 35898.73% from -$29.1 million recorded in Q1 2023.
  • In the past 5 years, RedHill Biopharma's EBITDA ranged from a high of $53.8 million in Q2 2023 and a low of -$128.0 million during Q4 2020
  • Its 5-year average for EBITDA is -$8.4 million, with a median of $3.1 million in 2019.
  • In the last 5 years, RedHill Biopharma's EBITDA tumbled by 28147.32% in 2021 and then soared by 35898.73% in 2023.
  • Over the past 5 years, RedHill Biopharma's EBITDA (Quarter) stood at -$72.9 million in 2019, then plummeted by 75.56% to -$128.0 million in 2020, then surged by 80.96% to -$24.4 million in 2021, then soared by 84.7% to -$3.7 million in 2022, then surged by 1541.46% to $53.8 million in 2023.
  • Its EBITDA stands at $53.8 million for Q2 2023, versus -$29.1 million for Q1 2023 and -$3.7 million for Q4 2022.